Audentes Therapeutics Promotes John Gray to Chief Scientific Officer

Xconomy San Francisco — 

Gene therapy developer Audentes Therapeutics (NASDAQ: BOLD) has promoted John Gray to senior vice president and chief scientific officer. Gray previously served as vice president of research and development for the San Francisco biotech. Before joining Audentes in 2014, Gray was assistant director of the Harvard Gene Therapy Initiative. Last year, Audentes raised $75 million in an initial public offering to fund clinical work on its gene therapies for rare diseases.